Director, Global Value and Health Economics and Outcomes Research

Jazz Pharmaceuticals

. Lead global and US payer evidence strategy across marketed assets in Jazz’s neurology portfolio .

Posted 11/5/2026full-timeRemote • United States, United KingdomLead💰 $212,000 - $318,000 per yearWebsite

Core Competencies

Role fit

Core Competencies

Use this summary to align your resume positioning with the role.

Expertise in Health Economics and Outcomes Research (HEOR) with a strong focus on developing and executing evidence strategies for biopharmaceutical products. Proven ability to collaborate across functions and lead complex projects, including economic modeling and post-marketing studies.

Highest-signal resume keywords

Health Economics ExpertiseComparative Effectiveness ResearchEconomic ModelingUS Managed Care KnowledgeHEOR Strategy Leadership

ATS Keywords

Tailor your resume

Applicant Tracking System Keywords

Tip: use these terms in your resume and cover letter to boost ATS matches.

Hard Skills

Economic ModelingComparative Effectiveness StudiesBudget Impact ModelingReal-World Evidence GenerationPost-Marketing HEOR StrategiesStatistical AnalysisSystematic Literature ReviewsMeta-AnalysisHealth Technology Assessment (HTA)Pharmacoeconomics

Soft Skills

Exceptional Verbal CommunicationStrong Written CommunicationPresentation SkillsMentoringCollaboration

Tools & Technologies

Healthcare DatabasesStatistical SoftwareInteractive Economic ModelsBudget ModelsAMCP Dossiers

Industry Keywords

Biopharmaceutical IndustryUS PayersPopulation HealthOncology PathwaysHealth PolicyValue Assessment BodiesRare DiseaseMarket AccessClinical DevelopmentRegulatory Affairs

About the role

Key responsibilities & impact

Lead global and US payer evidence strategy across marketed assets in Jazz’s neurology portfolio
Maximize brand potential, defend value, secure expanded access, and drive post-launch evidence generation
Lead HEOR evidence strategies for supplemental regulatory filings, new indications, line extensions, expanded populations, and novel formulations/devices
Partner with Medical Affairs, Clinical Development, and Biostatistics on Phase 3b/4 protocols, pragmatic trials, and expanded access programs
Develop comparative effectiveness and economic evidence for multi-indication lifecycles
Collaborate on rare disease registries, natural history extensions, and post-authorization safety/efficacy studies
Design rapid-response comparative effectiveness, adherence, and burden-of-illness studies against competitive threats
Co-create HTA re-assessment strategies and analytical packages with EU/INT HEOR teams
Direct updates to Global Value Dossiers, systematic literature reviews, and meta-analyses
Serve as designated US HEOR expert for assigned inline products
Lead AMCP dossiers, unbranded value summaries, and state Medicaid submission dossiers
Develop and train teams on interactive economic models and reactive scientific presentations
Ensure compliance with FDAMA Section 114, the 21st Century Cures Act, and FDA HCEI guidance
Evaluate outcomes-based risk-sharing agreements and establish claims/EHR tracking frameworks
Monitor US health policy and prepare evidence plans for ICER and other value assessment bodies
Formulate and execute cost-effectiveness, cost-utility, budget impact, and cost-offset modeling strategies
Build models incorporating mature clinical and real-world data
Represent GVHEOR in IEGP governance and align post-marketing studies with brand objectives
Partner with Market Access, Medical Affairs, Commercial Brand Leads, Regulatory Affairs, Biostatistics, and RWE
Lead publications, manuscripts, and presentations at scientific congresses
Manage budgets, HEOR consultancies, academic partners, and CROs
Mentor associate directors, managers, and fellows

Requirements

What you’ll need

Master’s degree (MSc, MS, MPH) or PhD in Health Economics, Outcomes Research, Pharmacoeconomics, or a closely related quantitative field
Minimum of 7–10 years of experience in HEOR, Global Value, or Health Economics within the biopharmaceutical industry or a top-tier HEOR consulting firm
Extensive experience designing and executing post-marketing HEOR strategies, real-world comparative effectiveness studies, and evidence roadmaps supporting label expansions, line extensions, and value defense
Comprehensive working knowledge of the US managed care landscape and global HTA environments
Proven technical expertise building, adapting, and validating economic models including Markov, partitioned survival, microsimulation, and dynamic budget impact models
Proven track record collaborating with US Market Access, Pricing/Contracting, and Payer Field Teams to develop compliant customer-facing tools, interactive budget models, and AMCP dossiers
Demonstrated understanding of rare disease post-launch evidence challenges
Working knowledge of major US and global healthcare databases and advanced epidemiological methods for comparative research
Ability to balance macro-level evidence strategy with hands-on execution of complex technical deliverables
Exceptional verbal, written, and presentation skills
Experience with oncology assets preferred
Deep understanding of US payers and population health decision makers including oncology pathways
Demonstrated track record leading HEOR strategy and executing evidence deliverables for marketed inline pharmaceutical products
Launch lead for at least 2 assets as US HEOR lead or country-level HTA lead
Strong peer-reviewed publication record in health economics and outcomes research

Benefits

Comp & perks

Discretionary annual cash bonus or incentive compensation
Discretionary equity grants
Medical insurance
Dental insurance
Vision insurance
401k retirement savings plan
Flexible paid vacation